Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) was downgraded by Wall Street Zen from a “sell” rating to a “strong sell” rating in a report released on Saturday, Wall Street Zen reports.
Several other analysts have also issued reports on the company. Royal Bank Of Canada set a $2.50 target price on Aardvark Therapeutics in a research note on Friday, October 23rd. HC Wainwright dropped their price target on Aardvark Therapeutics from $4.00 to $2.00 and set a “hold” rating on the stock in a research report on Monday, October 26th. Raymond James Financial reiterated a “market perform” rating on shares of Aardvark Therapeutics in a research note on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aardvark Therapeutics in a research note on Tuesday, September 29th. Finally, BTIG Research dropped coverage on Aardvark Therapeutics in a report on Monday, October 12th. They issued a “neutral” rating for the company. Two analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $11.56.
View Our Latest Research Report on Aardvark Therapeutics
Aardvark Therapeutics Stock Performance
NASDAQ:AARD opened at $1.33 on Friday. The stock has a market capitalization of $29.10 million, a PE ratio of -0.40 and a beta of 4.39. The firm’s 50 day moving average is $3.76 and its 200 day moving average is $5.72. Aardvark Therapeutics has a 12 month low of $0.93 and a 12 month high of $16.60.
Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) last posted its quarterly earnings data on Friday, November 13th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.19). Research analysts predict that Aardvark Therapeutics will post -3.05 earnings per share for the current year.
Insider Activity
In other news, insider Nelson Sun sold 62,000 shares of the firm’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $5.18, for a total value of $321,160.00. Following the completion of the transaction, the insider directly owned 35,475 shares of the company’s stock, valued at $183,760.50. This trade represents a 63.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 17.80% of the stock is currently owned by corporate insiders.
Institutional Trading of Aardvark Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in Aardvark Therapeutics in the 2nd quarter worth about $1,077,000. Marshall Wace LLP grew its holdings in Aardvark Therapeutics by 593.0% during the 3rd quarter. Marshall Wace LLP now owns 132,204 shares of the company’s stock valued at $697,000 after buying an additional 113,128 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Aardvark Therapeutics during the 1st quarter valued at about $267,000. J. Goldman & Co LP bought a new stake in shares of Aardvark Therapeutics during the second quarter valued at about $233,000. Finally, Ieq Capital LLC bought a new stake in shares of Aardvark Therapeutics during the second quarter valued at about $221,000.
About Aardvark Therapeutics
Aardvark Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California. It develops oral medicines for metabolic disorders, with a focus on conditions involving excessive hunger and disrupted energy balance. The company’s lead candidate, ARD-101, is an investigational oral therapy designed to activate bitter taste receptors in the gut and influence gut-brain signaling. Aardvark has studied the candidate for hyperphagia, or excessive hunger, associated with Prader-Willi syndrome and hypothalamic obesity.
See Also
- Five stocks we like better than Aardvark Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Aardvark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aardvark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
